Next Article in Journal
Synthesis and Biological Evaluation of Some New 3-Aryl-2-thioxo-2,3-dihydroquinazolin-4(1H)-ones and 3-Aryl-2-(benzylthio)quinazolin-4(3H)-ones as Antioxidants; COX-2, LDHA, α-Glucosidase and α-Amylase Inhibitors; and Anti-Colon Carcinoma and Apoptosis-Inducing Agents
Next Article in Special Issue
Cytotoxic Activity of Wild Plant and Callus Extracts of Ageratina pichinchensis and 2,3-Dihydrobenzofuran Isolated from a Callus Culture
Previous Article in Journal
Effects of Five Coumarins and Standardized Extracts from Tagetes lucida Cav. on Motor Impairment and Neuroinflammation Induced with Cuprizone
Previous Article in Special Issue
Analysis of Safety Concerns on Herbal Products with Assumed Phytoestrogenic Activity
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Ethnomedicinal Uses, Phytochemistry and Pharmacological Properties of Suregada Genus: A Review

1
Department of Chemistry, Tshwane University of Technology, Private Bag X680, Pretoria 0001, South Africa
2
Department of Chemistry, University of Kabianga, Kericho 2030, Kenya
3
Department of Chemistry, University of Pretoria, Private Bag X20, Pretoria 0001, South Africa
4
Biosciences, Council for Scientific and Industrial Research, Pretoria 0001, South Africa
5
Science Department, Royal Botanic Gardens, Kew TW9 3DS, UK
6
Department of Pharmaceutical Sciences, Tshwane University of Technology, Private Bag X680, Pretoria 0001, South Africa
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2023, 16(10), 1390; https://doi.org/10.3390/ph16101390
Submission received: 6 September 2023 / Revised: 25 September 2023 / Accepted: 27 September 2023 / Published: 30 September 2023

Abstract

:
Plants of the Suregada Roxb. ex Rottler (formerly Gelonium Roxb. ex Willd) are utilized to treat various ailments, namely, hepatic, gum diseases, pyrexia, eczema, and venereal diseases. This review links the reported compounds to ethnomedicinal uses through pharmacological activities. The compounds possess anticancer, anti-allergic, antibacterial, anti-inflammatory, antioxidant, and anti-HIV properties. From the previous reports, 32 known species of the Suregada genus have been investigated morphologically, and nine were investigated for their phytochemistry and pharmacology. Phytochemistry, ethnomedicinal, and pharmacological uses of the other 23 Suregada species are not known and/or not reported. In this review, abietane diterpenoids are the main compounds expressed by the Suregada, accounting for 71 of the 114 reported compounds. Ten triterpenoids and sterols, one aliphatic, two lignans, five flavonoids, and twenty-one nitrogen-containing compounds have been reported from the genus.

Graphical Abstract

1. Introduction

Suregada Roxb. ex Rottler (formerly Gelonium Roxb. ex Willd.) species are shrubs or small trees occurring in the forest, deciduous forest, or thicket with 32 accepted species, extending from Africa and Madagascar through India to southern New Guinea, China, Philippines, and northern Australia [1].
Based on morphology, Suregada was placed in Euphorbiaceae-Crotonoideae in the tribe Gelonieae with the monotypic Cladogelonium Leandri of Madagascar by Radcliffe-Smith in genera Euphorbiacearum [2,3]. Wurdack et al. stated that the relationship between these two genera was endorsed in a molecular phylogenetic study and was sister to the main clade of Crotonoid genera [4].
The genus Suregada is highly distinctive and cannot be confused with any other genus of tree or shrub in Sub-Saharan Africa. The combination of translucent gland dots in the leaves, leaf-opposed fasciculate or glomerulate inflorescences, and the node encircled by stipules (or stipular scars) separates it not only from all other genera in Euphorbiaceae but from all other genera with alternate simple leaves [2,3]. Suregada is best recognized by its leaf-opposed inflorescences; the whole plant is usually drying bright green and often has characteristic pustules within the leaf areoles [3].
The African species were last reviewed by Léonard when publishing the most recent African addition to the genus, S. croizatiana J. Léonard, a forest shrub from the Democratic Republic of Congo (DRC) [5]. The eight African species include Suregada africana Kuntze, and S. lithoxyla (Pax & K.Hoffm.) Croizat, S. zanzibariensis Baill, S. procera (Prain) Croizat, S. gossweileri (S.Moore) Croizat, S. ivorense (Aubrév. & Pellegr.) J. Léonard, S. croizatiana J. Léonard and S. occidentale (Hoyle) Croizat. Suregada africana is a shrub or tree that grows up to 3 m. It was the first described of the African species, and is southernmost in distribution, extending along the coast in the thicket and dry woodland from KwaZulu-Natal and Eastern Cape, through Eswatini to southern Mozambique [6]. Suregada zanzibariensis is sympatric with the former species in KwaZulu-Natal but reaches 10 m tall and extends in a coastal thicket up the coast of East Africa through Tanzania, Mozambique, and Kenya to southern Somalia, west to Angola, and east to Madagascar. Suregada procera is a forest shrub or small tree species, 3–8 m tall that also extends from KwaZulu-Natal northwards, in high altitude forests through Mozambique, Zimbabwe, Uganda, Zambia, Malawi, Tanzania, Kenya, eastern Democratic Republic of Congo (DRC) to South Sudan and Ethiopia [6]. Suregada lithoxyla is a forest shrub native to Tanzania, and S. gossweileri is a forest shrub of the Maiombe Mountains of Angolan Cabinda and DRC. The two West African species are Suregada ivorense, a tall forest tree endemic to the Ivory Coast, and S. occidentale (Hoyle) Croizat, a 2–3 m tall forest shrub of the Ivory Coast to western Cameroon [5,7]. Of the 32 species, pharmacological and phytochemical reports are available for only S. aequoreum Hance., S. adenophora Baill., and S. angustifolia Baill. S. boiviniana Baill, S. gaultheriifolia Radcl.-Sm, S. glomerulata (Blume) Baill., S. lanceolata (Willd.) Kuntze, S. multiflora (A. Juss.) Baill., and S. zanzibariensis Baill.
The medicinal application of Suregada species has been attributed to the presence of diverse chemical constituents such as diterpenoids, triterpenoids, flavonoids, etc. In particular, the diterpenoids about 73% isolated from Suregada species constitute the major chemical composition and exist as a diversity of different core skeletal frameworks. Diterpenoids, their chemical structure and biosynthesis pathways will be discussed. Significant research efforts have been made in isolating and evaluating the biological effects of phytochemicals from the roots, stems, stem barks, leaves, and whole plant extracts of the Suregada species. Although different reports have been published about the medicinal uses, chemical constituents, and biological activities of Suregada species, currently, there is no review on the phytochemicals, pharmacological, and ethnomedicinal uses of the genus Suregada. Thus, our objective is to provide comprehensive insights into phytochemicals, pharmacological, and ethnomedicinal uses from Suregada species. Furthermore, the authors previously isolated compounds, ent-abietane diterpenoids, an unknown compound trivially named Mangiolide (34), and Jolkinolide B (35) from the Suregada species. Through a review of the literature, we aim to identify gaps in current knowledge related to Suregada plant species and their compounds. These identified gaps can guide future research efforts, ensuring that the scientific community focuses on areas where further investigation is most needed. The information will serve as a guideline to the researchers and assist them in focusing their research on validating the claims made on the traditional folklore uses of the Suregada species and/or investigations to find new phytochemicals.

2. Literature Search Strategy

Information about the ethnomedicinal, pharmacological activities, structure, and occurrence, of action phytochemicals from Suregada species was obtained from publications extracted from Science Direct, PubMed, SciFinder, Springer Link, Wiley, Scopus, Google Scholar, and Web of Science databases. The databases were searched for research articles about Suregada species. The syntax TITLE-ABSTRACT-KEY was used in combination with keywords like ‘Suregada’ OR ‘genus’ OR ‘ethnomedicinal uses’ OR ‘constituents of Suregada’ OR ‘biological activities of Suregada phytochemicals’ OR ‘antibacterial’ OR ‘cytotoxic activity’ OR ‘antiviral’, OR ‘anti-inflammatory’. The search terms were run separately or as a combination of terms depending on the database used for the period between 2000 and 2022. The search resulted in over 100 reports mostly in the English language, which we retrieved at our institution. The reports obtained information on early documents on the taxonomy and research work articles on Suregada since historical times as well as current reports. The obtained information from about 50 articles was carefully read, to obtain the publications meeting the aim of this work with a few older publications to reveal some necessary points. Only published work on Suregada was selected for this review. Due to the lack of human clinical trials, studies based on both in vitro and in vivo conditions were contained within the review, but, only those studies that used isolated substances.

3. Medicinal Uses of Suregada Species

The medicinal uses of nine of the 32 Suregada plants are presented in Table 1 and described below.

3.1. Suregada adenophora Baill.

Suregada adenophora (Figure 1) occurs throughout Madagascar and is used as a purgative [8].

3.2. Suregada angustifolia (Müll.Arg.) Airy Shaw

Suregada angustifolia (Figure 1) is ground and mixed with water to prepare the paste, then applied to the body for the treatment of skin infections. When the S. angustifolia stem bark is boiled with water and salt, it can be utilized as a mouthwash for treating toothache. Indian people in Kanis use S. angustifolia to treat skin infections and toothache [9].

3.3. Suregada boiviniana Baill. (Suregada boiviniana var. boiviniana)

Suregada boiviniana (Figure 1) aids in evacuating the placenta and treating dysentery, headache, cold, epilepsy, and malaria [10,11].

3.4. Suregada decidua Radcl.-Sm.

The fresh sap of S. decidua (Figure 1) from Western Madagascar is used to promote wound healing [8].

3.5. Suregada lanceolata (Willd.) Kuntze

The shrub of the plant is used as an astringent [12]. S. lanceolata (Figure 1) is used for treating skin diseases, worms, blood vomiting, piles, toothache, and weakness [13].

3.6. Suregada lithoxyla (Pax & K.Hoffm.) Croizat

The wood of S. lithoxyla (Figure 1) is hard and used to make tool handles, spoons, firewood, and poles. The tree is suitable for ornamental purposes and is used for shade [14].

3.7. Suregada multiflora (A. Juss.) Baill.

Jahan et al. and Choudhary et al. stated that S. multiflora (Figure 1) is utilized to treat gum and hepatic ailments in traditional medicines [15,16]. According to the report of Tewtrakul et al., S. multiflorum is mixed with other herbs and used as an anticancer recipe, while in Thailand, it is used as a traditional medicine recipe (Table 1) [17]. Tewtrakul et al., further stated that the wood of S. multiflorum was used to treat pyrexia, eczema, and venereal diseases; the roots of this plant are utilized to treat skin infection and lymphatic disorders [17]. In Thailand, S. multiflora is utilized to treat skin diseases including rashes, itching, and inflammation [18]. In some regions, the granule products of this species can be prepared, which acts as a powerful organic herbicide [19]. In India, the seeds of S. multiflora are utilized in the treatment of liver diseases and as a gum tonic [20]. Suregada multiflora is harvested as timber to be used as firewood, rafters, and tool handles and cultivated as an ornamental [21,22,23].

3.8. Suregada procera (Prain) Croizat

This species is suitable for musical instruments, joinery, flooring, furniture, mine props, vehicle bodies, turnery precision equipment, interior trim, novelties, sporting goods, toys, agricultural implements, and draining boards [14]. The wood of S. procera (Figure 1) is hard and is used for firewood, handles, and poles in construction. The tree can be used for ornaments and shade [14]. The S. procera stem is used to treat hemorrhoids and gonorrhea. The stem of S. procera is burnt and fired in the affected area [24].

3.9. Suregada zanzibariensis Baill.

Tanzanian people used S. zanzibariensis (Figure 1) stem bark and root extract for treating ankylostomiasis. Its root extract is used to treat gonorrhea, stomachache, pneumonia, hernia, chest pains, and chicken pox, and as a purgative. The roots are drunk as an extract or chewed to treat snakebites, and Kenyan people use the roots to treat edema. Crushed leaves are ingested in porridge to expel worms and to treat dysentery. The powdered leaves are consumed in porridge or tea to treat poliomyelitis [25]. In Dares Salam, S. zanzibariensis leaves are boiled in water and applied topically or douched two times a day to treat vaginal candidiasis [26]. Tanzanian people mix S. zanzibariensis leaves with the Zanthoxylum chalybeum, and Acalypha fruticosa milled and scrubbed on the skin to treat skin infection [27]. Giriama and Duruma people use a root decoction to treat body swelling. Digo people use the root decoction for body pains, for pains during menstruation, and to avoid premature birth [28,29]. The wood of S. zanzibariensis is hard and used for tool handles, building poles, spoons, withies, and firewood. The tree is used for shade, soil conservation near the sea, and amenity. The roots are boiled, and the juice is drank twice a day as a purgative [14].
Figure 1. The plant species of Suregada (a) S. adenophora, (b) S. angustifolia, (c) S. boiviniana, (d) S. decidua, (e) S. lanceolata, (f) S. lithoxyla, (g) S. multiflora, (h) S. procera, (i) S. zanzibariensis [1,30,31,32,33].
Figure 1. The plant species of Suregada (a) S. adenophora, (b) S. angustifolia, (c) S. boiviniana, (d) S. decidua, (e) S. lanceolata, (f) S. lithoxyla, (g) S. multiflora, (h) S. procera, (i) S. zanzibariensis [1,30,31,32,33].
Pharmaceuticals 16 01390 g001
Table 1. Some reported ethnomedicinal uses of Suregada species.
Table 1. Some reported ethnomedicinal uses of Suregada species.
PlantPlant PartUsesReferences
S. adenophoraUnspecifiedPurgative[8]
S. angustifoliaStem barkSkin infections, toothache[9]
S. boivinianaUnspecifiedPurgative[10]
LeavesHeadaches and cold, dysentery, malaria, placenta apposition and epilepsy[10,11]
S. deciduaFresh sapWounds[8]
S. lanceolata/S. angustifoliaShrubAstringent[12]
Whole plantSkin diseases, worms, weakness, blood vomiting, piles, toothache[13]
S. lithoxyliaWoodPoles, fuel, spoons, tool handles[14]
S. multifloraWoodEczema, venereal diseases, and pyrexia[17]
RootsLymphatic disorders, skin diseases
BarkLymphatic disorder, hepatitis, skin diseases, fungal infection, venereal diseases, and leprosy
Whole PlantPneumonia, fever, poisonous effects, stomach disorder, squint eye, and gum disease
S. proceraWoodPoles, handles, and firewood[14]
TreeOrnaments and shade
StemHemorrhoids, gonorrhea[24]
S. zanzibariensisLeavesAsthma, malaria, skin diseases, dysentery, vaginal candidiasis and abdominal pains[21,26,27,29]
Roots and stem barkAnkylostomiasis[25,29]
RootsGonorrhoea, chest pain, stomach ache, hernia, chicken pox, schistosomiasis, body swelling, pneumonia and purgative[14,25]
WoodBuilding poles, tool handles, withies, fuel and spoons[14]

4. Phytochemical Composition of the Suregada Genus

Although Suregada species are more valued plant species for their medicinal properties, only a few species have been studied for their ethnomedicinal and phytochemistry. There are wide discrepancies among the published results on the species’ primary metabolite content with diterpenoids frequently isolated. The literature reports 114 phytochemicals from the genus Suregada which were classified into diterpenoids (171), triterpenoids (7281), alkaloids (8284), flavonoids (8590), lignans (9294), amino acids (95104) and iminosugars (105114) [1,15,16,34,35] as shown in Figure 2. Diterpenoids were the major constituents reported from the genus. Most of the isolated metabolites were not evaluated for their pharmacological properties which limits their transition to clinical trials. The reports show that the phytochemical investigation of Suregada species has not been explored fully. Hence, future studies should aim at exploring the phytopharmacological properties of Suregda species.

4.1. Diterpenoids

Diterpenoids are a class of natural products known for their structural diversity. Diterpenoids isolated from Suregada genera belong to ent-abietane, diterpene lactone, ent-kuarane, and ent-pimaranes classes [36,37]. Ditepenoids consist of four isoprene units which form a 20-carbon backbone. The core structures for diterpenoids are classified into macrocyclic, bicyclic, linear, tricyclic, tetracyclic, and pentacyclic types [38]. Naturally, occurring diterpenoids are often found in different polyoxygenated forms with hydroxyl groups, formyl and carbonyl groups, or lactones. There are different types of diterpenoids such as ent-abiatane (159), ent-kaurane (6071), etc. Ent-abietane diterpenoids were reported to exhibit a wide spectrum of biological activities such as cytotoxic, anti-microbial, anti-cancer, and anti-inflammatory [39]. Ent-Abietanes with a lactone ring are classified as one of the main bioactive compounds. For example, jolkinolide B (35) is well-known for its anti-tumor activity [39]. Ent-abietanes diterpenoids often contain an α, β-unsaturated γ-lactone ring. Some carbons of abietane diterpenoids, form a double bond or are substituted with hydroxyl or keto groups [40]. The varying skeletal structures of diterpenes result from geranylgeranyl pyrophosphate (GGPP) and are classified according to their biosynthetic pathways and cyclization patterns [41]. According to Dewick diterpenes start from geranylgeranyl diphosphate (GGPP), formed by the addition of an isopentenyl diphosphate (IPP) molecule to Farnesyl diphosphate (FPP) [41]. Cyclization of GGPP mediated by carbocation formation, allows many structural alternatives of diterpenoids to be formed [41]. Dewick further mentioned that during cyclization, the loss of diphosphate occurs which generates the first carbocation, and several natural diterpenes have been formed by varying mechanisms through cyclization [41].
The formation of carbocation formation begins by protonation of the double bond at the head of the chain, which leads to the initial cyclization sequence. Furthermore, the loss of the diphosphate later on gives rise to a carbocation and causes further cyclization. Protonation of GGPP can start a joint cyclization sequence, the loss of a proton from a methyl terminates the cyclization sequence, producing (−)-copalyl PP [41]. Folding of the substrate on the enzyme surface controls the stereochemistry of (−)-copalyl PP. Nevertheless, alternate folding results in (+)-copalyl PP (labdadienyl PP), the enantiomer of (−)-copalyl PP, which has an opposite configuration at the newly produced chiral centers. From (−)-copalyl PP, several cyclizations and a rearrangement, all catalyzed by a single enzyme kaurene synthase, produce ent-kaurene [42]. Formation of ent-kaurene involves the loss of the diphosphate leaving group which enables the carbocation-mediated product of the third ring system, which then forms the fourth ring [41].
Earlier the biosynthesis of ent-kaurane was described, the latter is the suggested biosynthesis of ent-abietane diterpenoid. The suggested biosynthesis of ent-abietane lactones is shown in Scheme 1 [42]. Some of the ent-abietane lactones including Jolikinolide (35) may be biosynthesized from the ent-neoabietadiene. The oxidation of ent-neoabietadiene could lead to an intermediate labeled (a). Then, the intermediate (a) might be oxidized to obtain intermediate (b) and (c) [42]. The highly oxidized ent-abietane diterpenoid skeleton (c) may undergo a series of intramolecular cyclization, oxidation, and dehydration reactions to produce the ent-abietane diterpenoids bearing an additional five-membered lactone ring, including 35 [42].
Studies conducted on Suregada indicated the presence of several types of diterpenoids. In particular, compounds 159, the ent-abietane diterpenoids containing an additional five-membered lactone ring, revealed important pharmacological anti-tumor and anti-inflammatory activities to name a few. The specific functional groups besides the lactone ring in these ent-abietane diterpenoids can differ depending on the compound’s biosynthetic origin and its specific modifications [43]. These functional groups such as hydroxyl, epoxide, acetates, ketones, and alkene collectively contribute to the compound’s chemical and biological properties, making ent-abietane diterpenoids a diverse group of natural products with various potential applications in pharmacology, medicine, and other fields of research. The biological activities of ent-abietane diterpenoids are often related to their interactions with specific molecular targets in biological systems, and the presence of particular functional groups can be crucial for these interactions [43].
Diterpenoids are named by making use of the main name of their skeletons. If the backbone of the diterpenoid comprises many functional groups namely carboxylic, aldehyde groups, lactone, or olefinic carbons, their position will be named according to the numbering of the skeleton, and the name will be followed by the suffix -oic, -al, -olide, or -en, respectively [43]. The presence of hydroxyl and epoxide groups is named before the parent name. Greek letters α or β are utilized when a hydroxyl, epoxide, acetoxyl, or coumaroyl group in the compound is, respectively, upon or behind the plan of the skeleton [Sandjo, Rubinger] such as compounds 33, 3641, etc. The location of epoxide, hydroxyl groups, and other substituents in the diterpene cores are given between the terms ent, syn, or neo and the name of the skeleton. The stereochemistry at C-9 and C-10 in the decalin part (ring A and B) of most diterpenoids can be cis or trans, depending on their orientation, and the naming syn and ent are utilized. When C-20 and C-11 are behind the compound plan, the prefix ent will follow the parent name [43].
The number of carbons (20 signals of carbons) seen on the 13C-NMR spectrum could suggest that the compound is a diterpenoid. Moreover, some of the abietane, kaurane, and labdane scaffolds that do not possess any functional group on the decalin moiety such as compounds 10 and 35 exhibit carbon signals of C-1 (CH2), C-2 (CH2), C-3 (CH2), C-5 (CH), and C-6 (CH2) around δ 40.1, 18.2, 42.0, 56.0, and 20.0, respectively [44] (Figure 3c). Methyl groups C-18, 19, and 20 are seen around δ 33.1, 21.5, and 18.0, respectively. Both C-18 and 19 have Heteronuclear Multiple-Bond Correlation spectroscopy (HMBC) interactions and they correlate with C-3 (δ 42.0), C-4 (δ 33.1), and C-5 (δ 56.0) [43,44]. Ent-abietanes diterpenoids usually contain an α, β-unsaturated γ-lactone ring connected at C-12 and C-13. Some carbons of abietane diterpenoids, like C-8, C-14, C-11, and C-12, form a double bond or can be substituted with hydroxyl or keto groups [40]. According to the reports obtained from the search, the structure–activity relationship of compounds isolated from Suregada species was not evaluated. The structure–activity relationship of some reported diterpenes revealed that acetylation and esterification of hydroxyl groups, particularly at C-3 and C-8, have a positive effect on activities [40].
The 1H NMR spectrum of compound 4 (Figure 1) showed the presence of a trisubstituted cyclopropane ring. Two upfield resonances of the C-18 cyclopropane methylene protons H-18 (exo), δH −0.01, and H-18 (endo), δH 0.40 at δC 21.8, the H-3 signal at δH 0.54 at δC 19.1, and one quaternary carbon resonance (C-4, δC 16.1) confirmed the presence of a trisubstituted cyclopropane ring in ring A. Jahan further confirmed that these values aligned with the values reported for the metasequoic acids that were reported as a novel skeleton from the investigation of phytochemicals from Merasaquoia glyptostroboide [45] containing a trisubstituted cyclopropyl substituent in ring A of a labdane skeleton. Compounds 5, 6, and 7 had similar NMR signals that indicated the presence of a cyclopropane group. All these compounds were deduced to have a rearranged abietane skeleton [34]. The cyclopropyl ring on the ent-abietane or ent-abietane lactones is rare. Several modified pimarane diterpenoids and tiglianes contain the cyclopropane system [45].
Kalenga reported that modified ent-abietane diterpenoids with a terminal olefinic bond at C-4, such as in compounds 58 and 59, are rare. The terminal double bond at C-4 is proposed to arise through an enzymatic 1,2-methyl shift, either of CH3-18 or CH3-19, from C-4 to C-3, followed by dehydrogenation [46]. The suggested biosynthesis for compounds 58 and 59 is shown in Scheme 2 [46]. The oxidation of ent-copalyl PP leads to the production of ent-pimaradiene. Then, the ent-pimaradiene could be oxidized to obtain an intermediate containing a lactone ring which is an ent-abietane diterpenoid skeleton. The ent-abietane diterpenoid skeleton may undergo a series of transformations namely, hydrogenation, and dehydrogenation, and then followed by enzymatic 1.2 methyl shift to produce compound 58 or epoxidation for compound 59 [46].
The chemical structures of the diterpenoids isolated from Suregada species are discussed below.

4.2. Abiatane-Type Diterpenoids

Abietanes are tricyclic diterpenoids found in nature that have been isolated from a variety of terrestrial plant sources. Araucariaceae, Cupressaceae, Phyllocladaceae, Pinaceae, and Podocarpaceae families, as well as some species from Asteraceae, Celstraceae, Hydrocharitaceae, and Lamiaceae families, and even some fungi species, are known to contain abietane diterpenoids. Abietane diterpenoids have a wide range of biological activities. Apart from the antimicrobial, antiviral, antimalarial, antiulcer, anti-leishmaniasis, and antioxidant activities reported by the scientists, they also reveal antitumor-promoting activity and antivirus properties by inhibiting the reproduction of viruses such as herpes simplex virus type 1 (HSV-1), cytomegalovirus (CMV), varicella zoster virus (VZV), and Epstein-Barr virus [17,36,47]. Aromatic abietanes are the most abundant abietane group. Aromatic abietanes are primarily represented by dehydroabietic acid and ferruginol. Aromatic abietanes, like most diterpenoids, are mostly known as chemical defense agents. Antimicrobial, antileishmanial, antiplasmodial, antifungal, antitumor, cytotoxicity, antiviral, antiulcer, cardiovascular, antioxidant as well and antiinflammatory activities are the biological activities of this group reported up to now. Various diterpenoids have been assigned structures that could be derived by adjusting or cleaving the abietane skeleton, known as rearranged abietane. Triptergulides A and B are novel rearranged abietane diterpenes isolated from Tripterygium wilfordii (Celastraceae), a medicinal plant used in Traditional Chinese Medicine to treat a variety of diseases including systemic lupus erythematosus, psoriasis, ankylosing spondylitis, and idiopathic IgA nephropathy. Over 59 (1–59) ent-abietane-type diterpenoids were isolated from Suregada species which remains the abundant diterpenoids from the genus.
Ent-abietane and ent-kuarane diterpenoid lactones were isolated from S. multiflora, S. glomerulata, S. aequorea and S. zanzibariensis. The dichloromethane extract of S. multiflora bark afforded three tetracyclic diterpene lactones; helioscopinolide A (1), helioscopinolide C (2) and helioscopinolide I (3) (Figure 1a) [17,36]. Suregadolides A and B (4 and 5) were isolated from the dichloromethane extract of S. multiflora bark (Figure 1a). Dichloromethane-methane extract of S. multiflora bark afforded suregadolides C (6) and D (7) (Figure 1a) these compounds were found to possess a novel skeleton, containing a cyclopropane ring bridging at C-3 and C-4 of the abietane skeleton [16,34]. Gelomulides A-F (813) were isolated from the S. multiflorum leaves (Figure 1a) [48]. S. multiflora leaves were reinvestigated and led to the isolation of Suremulide A (14) and gelomulides G-J (1518) (Figure 3a) [15,16,34,49].
Lee et al. reported the isolation of ent-abietane diterpenes, namely, gelumolide K-X (1932) (Figure 3a,b) and 6β-acetoxy-1-one-8β,14-α-dihydroxy-ent-abieta2(3),13(15)-diene,12-olide (33) [35] from the dichloromethane extract of S. aequorea.
Mangisa et al., isolated 6-acetoxy-14-keto-ent-abieta-7(8),13(15)-diene-16,12-olide) trivially named mangiolide (34) and 8,13-diepoxy-13,15-ent-abietene-16,12-olide, Jolkinolide B (35) from the dichloromethane-methanol extract of S. zanzibariensis, (Figure 3b) [50].
Ent-abiatene diterpenoids 7β,8αβ-dihydroxy-12-oxo-ent-abietan-16,14-olide (36), 3,4,18β-cyclopropa-7β,17-dihydroxy-ent-abieta-8(14),13(15)-dien-16,12-olide (37), 3α,7β-dihydroxy-ent-abieta-8(14),13(15)-dien-16,12-olide (38), 7β-hydroxy-ent-abieta-8(14),13(15)-dien-16,12-olide (39), 3-oxo-8β,14β-epoxy-ent-abieta-11,13(15)-dien-16,12-olide (40), 13α-Hydroxy-14α,16-epoxy-ent-abieta-7-en-3-one (41), 7-Oxo-ent-abieta-5,8(14),13(15)-trien-16,12-olide (42), Methyl 12-hydroxy-3-oxo-ent-abieta-8,11,13-trien-17-oate (43), 3-oxo-jolkinolide B (44), 3,4,18b-cyclopropa-ent-abieta-8(14),13(15)-dien-16,12-olide (45) and 7β,17-dihydroxy-ent-abieta-8(14),13(15)-dien-16,12-olide (46) were isolated from the ethanol extract of S. glomerulata roots (Blume) Baill. [51,52,53].
Dichloromethane-methanol extract of S. multiflora leaves afforded 3β-Hydroxy-8,14β:11,12α-diepoxy-13(15)-abietane-16,12-olide (47) [53]. Investigation of methanol-dichloromethane (1:1) extract of S. multiflora leaves afforded ten diterpene lactones namely, 3β,6β-diacetoxy-1-one-8β,14β-epoxy-13,15-abiatene-16,12-olide (48), 3β-hydroxy-1-one-8β,14β-epoxy-13,15-abiatene-16,12-olide (49), 3β-acetoxy-8β,14α-dihydroxy-13,15-abiatene-16,12-olide (50), 6β-acetoxy-2-ene-8β,14α-dihydroxy-1-one-13,15-abiatene-16,12-olide (51), 3β-acetoxy-8β,14α-dihydroxy-1-one-13,15-abiatene-16,12-olide (52), 3β-acetoxy-8β,14β-epoxy-13,15-abiatene-16,12-olide (53), 3β,6b-diacetoxy-8β,14β-epoxy-13,15-abiatene-16,12-olide (54), 3β-acetoxy-1-one-8β,14β-epoxy-13,15-abiatene-16,12-olide (55), 2-ene-1-one-8β,14β-epoxy-13,15-abiatene-16,12-olide (56), and 6β-acetoxy-2-ene-1-one-8β,14β-epoxy-13,15-abiatene-16,12-olide (57) [15]. S. zanzibariensis leaf extract yielded zanzibariolides A (58) and B (59) [46].

4.3. Kaurene-Type Diterpenoids

Cheenpracha et al., Jahan et al., and Tewtrakul et al. investigated the active dichloromethane extract of the S. multiflora stem bark which yielded several diterpenoids ent-kaurene diterpenoids, ent-16-kauren-3β,15β,18-triol (60), and ent-3-oxo-16-kauren-15β,18-diol (61) together with ent-16-kaurene-3β,15β-diol (62), and abbeokutone (63) (Figure 4) [16,17,36]. According to Gondal, Jahan et al., and Tewtrakul et al., Suremulol A (64) and Suremulol B (65) were also isolated from S. multiflora (Figure 2) [16,17,51]. He et al., and Yan et al., stated that the ethanol extract of S. glomerulata roots yielded 1α,16α,17-Trihydroxy-ent-kaurane (66), euphoranginol B (67), corymbol (68), and ent-kaurane-3β,16β,17-triol (69) (Figure 4) [52,53].

4.4. Ent-Pimarane Diterpenoids

Jahan et al. investigated S. multiflora which yielded bannaringaolide A (70) (Figure 5) [16]. A diterpene lactone of an ent-pimarane skeleton, 17-hydroxy-ent-pimara-8(14),15-dien-3-one (71) was isolated from the ethanol extract of S. glomerulata roots [52].

4.5. Triterpenoids

Sengupta and Khastgir reported the isolation of three triterpenoids, namely: 7-multifloren-3β-ol (72), 7-multifloren-3α-ol (73), and baurenol (74) (Figure 6) from the bark extract of S. multiflora [54]. Baurenol (74) was also isolated from S. angustifolia. Venkatesan et al. reported six compounds, epi-friedelinol (75), friedelin (76), and α-amyrin (77) from S. angustifolia stem bark [9]. α-amyrin (77) and simiarenol (78) were also isolated from S. zanzibariensis leaves extract [46].

4.6. Fatty Alcohol, Steroidal Glycoside and Phytosterol

n-Octacosanol (79), β-sitosterol-3-β-D-glucopyranoside (80), and β-sitosterol (81) were isolated from S. angustifolia stem bark [9].

4.7. Alkaloids

Yan et al. explored S. glomerulata leaves (Blume) Baill., which afforded three pyrrolidine alkaloids, namely 5β-carboxymethyl-3α-hydroxy-2β-hydroxymethyl-1,1-dimethylpryrrolidine (82), 5β-carboxymethyl-3α-hydroxy-2β-hydroxymethyl-1-methylpryrrolidine (83) and 2α-carboxymethyl-5α-dimethylamino-4α-hydroxy-tetrahydrpyran (84) (Figure 7) [52]. Polyhydroxyalkaloids such as trimethylsilyl (TMS) derivatives of α-homonojirimycin were isolated from S. gaultheriifolia Radcl.-Sm leaves and S. adenophora leaf fragment [55].

4.8. Flavonoids

Flavone-type flavonoids have been isolated from Suregada species [56]. Flavone glycosides, gelomuloside A (85) and B (86); flavone glycoside, 7,4’-O-l-ramnopyranosyl (12)-d-glucopyranoside (87) (Figure 8), resulted from the investigation of seeds of S. multiflora. Three other flavones were obtained from the isolation of the leaves of S. multiflora, namely, kanugin (88), dimethoxy kanugin (89), and pinnatin (90) (Figure 8) [57]. Das and Chakravarthy reported the isolation of a flavone glycoside, luteolin-7,4′-dimethyl ether 3′-glucoside (91) from the S. multiflora leaf extract (Figure 9) [57,58].

4.9. Lignans

Gondal and Choudhary isolated two lignans, pinoresinol (92) and syringaresinol (93), from the methanol extract of leaves of S. multiflora (Figure 9) [15,47].

4.10. Amino Acids

The leaves of S. glomerulata were investigated and afforded twelve amino acids, namely, alanine (94), glutamic acid (95), leucine (96), isoleucine (97), proline (98), γ-aminobutyric acid (99), (R)-carnitine (100), lysine (101 (Figure 10) [53].

4.11. Pyrimidines, Purine Nucleoside and Pyridines

Uracil (102), uridine (103), guanosine (104), and 3H-imidazo [4,5-c]pyridine (105) (Figure 11) were isolated from The leaves of S. glomerulata [53].

4.12. Pyrrolidine-Type Iminosugars

The water extract of Suregada glomerulata leaves afforded ten pyrrolidine-type iminosugars, namely: 7-deoxy-homoDMDP (106), 6-deoxy-homoDMDP (107), 2,5-imino-2,5,6-trideoxy-D-gulo-heptitol (108), 2,5-imino-2,4,5-trideoxy-D-manno-heptitol (109), 2,5-imino-2,4,5-trideoxy-D-gulo-heptitol (110), 2,5-imino-2,4,5,6-tetradeoxy-D-gulo-heptitol (111), 6-C-butyl-DMDP (112), 6-C-butyl-4-deoxy-DMDP (113), 6-C-(8-hydroxyoctyl)-DMDP (114) and 6-C-(8-hydroxyoctyl)-2,5-dideoxy-2,5-imino-D-galactitol (115) (Figure 12) [59].

5. Pharmacological Activities of the Suregada Genus

The reviewed published article revealed that some of the isolated phytochemicals were tested for their pharmacological activities while some were not evaluated. Suregada species and some phytochemicals were screened for their antileishmanial, antidiabetic, antioxidant, cytotoxic, anti-plasmodial, antimicrobial, and anticancer activity. A summary of some Suregada species activities is presented in Table 2.

5.1. Antibacterial and Antimicrobial Activity

Venkatesan et al., reported the screening of methanol, chloroform, and hexane extracts of S. angustifolia stem bark at various concentrations (20, 10, and 5 mg·mL−1) against twelve human pathogenic bacteria [9]. The maximum zone inhibition at 20 mg·mL−1 in chloroform extract was observed as Klebsiella pneumonia (37 mm), Staphylococcus aureus (32 mm), A. hydrophila (40 mm), and Escherichia coli (40 mm). In comparison, the observations at 10 mg·mL−1 were slightly different observed as E. coli (32 mm), K. pneumoniae (30 mm), S. aureus (25 mm), and A. hydrophila (33 mm) [9]. Hexane extract at 20 mg·mL−1 revealed inhibition against K. pneumonia (29 mm), A. hydrophila (30 mm), Proteus vulgaris (25 mm), V. parahaemolyticus (25 mm), V. vulnificus (25 mm) and V. cholera (25 mm). The methanol extract at 20 mg·mL−1 showed zone inhibition against S. aureus (32 mm), E. aerogenes (26 mm), E. coli (26 mm), and P. vulgaris (25 mm) [9].
Aqueous, chloroform, and ethanol extracts of S. angustifolia bark and leaves were screened against two bacterial strains (Gram-positive and negative) and two fungal strains using the disc diffusion method. The aqueous leaf extract revealed zone inhibition of Pseudomonas aeruginosa (18.00 mm) and Bacillus subtillis (8.00 mm). The aqueous extract of S. angustifolia bark revealed zone inhibition of P. aeruginosa (20.00 mm) and B. subtillis (15.00 mm). The chloroform bark extract showed antibacterial properties against P. aeruginosa and B. subtilis with zone inhibition values of 18.00 mm and 15.00 mm. The ethanol leaf extract revealed activity against P. aeruginosa, S. aureus, and B. subtilis with zone inhibition values of 9.00 mm, 20.00 mm, and 12.00 mm, respectively [25].
The antibacterial activity of S. multiflorum leaves, bark, and stem extracts was investigated. The leaves hexane extracts revealed partial zone inhibition against Mycobacterium lacticola and S. aureus (10 to 11 mm). The hexane extract of S. multiflorum bark showed zone inhibition of 10 mm against S. aureus. The leaf dichloromethane extracts partially showed zone inhibition of 10 mm against S. aureus, 0.5 mm against E. coli, and 11 mm against M. lacticola and moderately revealed zone inhibition of 16 mm Bacillus subtilis [60]. The bark dichloromethane extracts showed a moderate zone inhibition of 12 to 13 mm, 15 mm, 13 to 14 mm, and 12 to 13 mm against S. aureus, B. subtilis, M. lacticola, and Xanthomonas campestris, respectively. The stem hexane extract revealed partial inhibition against M. lacticola with a zone inhibition value of 11 mm. The stem-dichloromethane extracts showed partial zone inhibition of 0.3 mm against E. coli and 3 mm against X. campestris and moderate inhibition against S. aureus, B. subtilis, and M. lacticola with zone inhibition of 13 mm, 13 mm and 18 mm, respectively [60]. The dichloromethane extract was the most active extract, followed by hexane and methanol extracts [60].
The (1:9) methanol-ethyl acetate extract of S. multiflora leaves and root was investigated against four gram-negative and five gram-positive bacterial strains at a dose of 200 µg.disc-1. Suregada multiflora root extract revealed a promising antimicrobial effect against B. subtilis, Shigella boydii, E. coli, S. aureus, B. cereus, B. megatherium, B. anthracis, Shi. flexneri and P. aeruginosa with the zone inhibition values of 12 ± 0.05 mm, 12 ± 0.07 mm, 13 ± 0.01 mm, 12 ± 0.07 mm, 11 ± 0.13 mm, 10 ± 0.22 mm, 11 ± 0.02 mm, 10 ± 0.01 mm, 11 ± 0.12 mm, and 9 ± 0.05 mm, respectively, with E. coli being the highest [61]. The S. multiflora leaf extract showed mild potency when screened against B. subtilis, S. aureus, and Shi. flexneri, E. coli, and Pseudomonas aeruginosa with the zone inhibition range of 5 ± 0.05 to 6 ± 0.05 mm [62]. Since significant activity was observed in all the tested bacterial strains for the root extract, minimum inhibitory concentration (MIC) values were only applied to the root extract. E. coli was the most sensitive, with a MIC of 0.625 mg/mL [61]. S. multiflora root extract further revealed a maximum relative percentage inhibition against Shi. boydii (34.45%), B. subtilis (32.12%) and E. coli (41.23%) at 200 µg·mL−1 dose. The leaf extract of S. multiflora showed a relative percentage range between 11.21 and 14.53%, and the applied dosage was 200 µg·mL−1 [61].
Helioscopinolide A (1) isolated from S. multiflora (1) showed an antibacterial effect against S. aureus 6538P (2.5 µg·spot−1) [62]. Epifriedelinol (75) isolated from S. multiflora was previously screened against seven Gram-negative bacterial strains, namely, K. pneumoniae, P. aeruginosa, Salmonella typhimurium, E. coli, and Shi. Flexneri, Proteus vulgaris, and Shi. sonnei and five Gram-positive bacterial strains, namely B. subtilis, B. pumilus, B. cereus, Micrococcus luteus and S. aureus [59]. Epifriedelinol (75) revealed zone inhibition Grange of 14.00 ± 0.58 to 25.66 ± 0.88 mm against all the Gram-positive and negative bacterial strains with the MIC range of 6.25 and 50 µg·mL−1 and the minimum bactericidal concentration (MBC) range of 12.5 and 100 µg·mL−1. Epifriedelinol (75) was the most sensitive against S. aureus, with a zone inhibition of 25.66 ± 0.58 mm. MBC of 12.5 µg·mL−1 and MIC of 6.25 µg·mL−1. Epifriedelinol (75) revealed lower activity against K. pneumoniae with a zone inhibition value of 14 ± 0.88 mm. MBC of 100 µg·mL−1 and MIC of 50 µg·mL−1 [60,63].

5.2. Insecticidal Activity

The (1:9) methanol: ethyl acetate extract of S. multiflora root revealed a 100% mortality rate for Tribolium castaneum at 50 mg·mL−1 dose in 12 h, while leaves extract revealed a mortality rate of 40% for Tribolium castaneum at 50 mg·mL−1 dose in 48 h. Strong insecticidal activity was observed on the S. multiflora root extract. A dose-dependent manner was carried out, where five graded doses, namely, 5, 10, 20, 30, and 40 µg·mL−1 were utilized, and the mortality rate was 33.33%, 53.33, 86.66, 93.33, and 100, respectively [61].

5.3. Antifungal Activity

Jahan et al. stated that Suregadolide A (4) isolated from S. multiflora revealed an antifungal effect of minimum concentration that produces zone inhibition of 12 mm diameter (IC12) of 70 and 35 µg·mL−1 in the RAD+ and RAD52 mutant yeast assays, respectively [34].

5.4. Anticancer Activity

In 2008, Lee et al. published that the dichloromethane extract of S. aequoreum was active against several human cancer cells with IC50 < 20 µg·mL−1 [36]. Yan et al. stated that S. glomerulata roots were tested against five tumor human cancer cells, namely, liver cancer (Bel 7402), ovarian (A2780), lung cancer (A549), stomach (BGC 823) and colon (HCT-8) and showed weak cytotoxic effects against all the cancer cells [54]. S. zanzibariensis stem bark (1:1) dichloromethane-methanol extract was screened at 100 µg·mL−1 dose to evaluate anticancer properties against melanoma (UAC62), breast (MCF7) and cells renal (TK10). The (1:1) dichloromethane-methanol extract was potent against TK10, UACC62 and MCF7 cancer cells with the Total Growth Inhibition (TGI) of 0.60 µg·mL−1, 0.54 µg·mL−1 and 5.27 µg·mL−1, respectively, and 50% Growth Inhibition (GI50) of 0.25 µg·mL−1 for UACC62, 0.26 µg·mL−1 for TK10 and 0.81 µg·mL−1 for MCF7 [51]. Helioscopinolide A (1) was potent against breast adenocarcinoma (MCF-7) and lung cancer (NCI-H460) with GI50 of 67.50 ± 3.04 µM and 72.78 ± 6.33 µM [64] and inhibited anticancer activity against human cervical carcinoma (HeLa) (IC50 = 0.11 µM) and breast cancer (MDA MB-231) (IC50 = 2.1 µM) cells [65]. Gelomulide E (12) isolated from S. multiflora was potent at a concentration of 5x10-5 M against the lung (NCI H490) cancer cell with growth inhibition of more than 85% [62]. Gelomulide E (12) was screened in a panel of 60 tumor cells and was reported to show activity against leukemia (CCRF-CEM), leukemia (SR), leukemia (K-562), breast (MD MB-435), and colon (HTC-15) with more than 95% growth inhibition [56].
Gelomulide K (19) and M (20) isolated from S. aequorea afforded moderate cytotoxicity activities against breast (MCF7 and MB-231), liver (HepG2), and lung (A549) with the IC50 range of 10.5 to 29.8 µM [35]. Gelomulide K (19) suppressed the growth of breast cancer cells, such as MDA-MB-231, BT474, MCF-7, MDA-MB-468 and SKBR3, with the IC50 range of 25.30 to 37.84 µmol·L−1 [49]. Mangiolide (34) isolated from S. zanzibariensis exhibited anticancer activities with TGI values of 0.02 µg·mL−1 (TK10), 0.03 µg·mL−1 (UACC62) and 0.05 µg·mL−1 (MCF7) and the GI50 values 0.07 µg·mL−1 (TK10); 0.06 µg·mL−1 (UACC62) and 0.33 µg·mL−1 (MCF7). Jolkinolide B (35) isolated from S. zanzibariensis showed anticancer properties with the TGI of 13.99, 5.03 and 62.03 µg·mL−1 against TK10, UACC62 and MCF7 cancer cells, respectively, and GI50 values of 0.94 µg·mL−1 for UACC62, 3.31 µg·mL−1 for TK10 and 2.99 µg·mL−1 for MCF7 and further exhibited selectivity against melanoma (UACC62) [50].
Jolkinolide B (35) reduced the production of lactic acid and ATP and induced tumor cell apoptosis in mouse melanoma B16F10 cells. Jolkinolide B (35) showed a low level of the mRNA expression of glycolysis-related kinase genes (Ldha and Hk2) in B16F10 cells and glucose transporter genes (Glut1, Glut3, and Glut4) [66,67,68]. Jolkinolide B (35) showed an increased level of the mRNA expression of pro-apoptosis genes (Bax) and reduced the rate of the mRNA expression of anti-apoptosis genes (Caspase-3, Caspase-9, and Bcl-2) which confirms its anticancer effect. It improved reactive oxygen species (ROS) levels in B16F10 cells and reduced the mitochondrial membrane potential [65,66,67]. Jolkinolide B (35) was reported to induce the tumor apoptosis of murine melanoma B16F10 cells in a mouse xenograft model and suppress tumor growth. Jolkinolide B (35) induced apoptosis viability and decreased cells in a time- and dose-dependent manner in human leukemic (U937) [62]. Jolkinolide B (35) decreased the colony formation and cell viability of HT29, CRC, and SW620 cells [65,66,67]. Jolkinolide B (35) showed phosphorylation of extracellular signal-regulated kinase (ERK) [68]. According to Luo et al., Jolkinolide B (35) showed the linkage of MDA MB 231 cells to fibronectin [68]. Jolkinolide B (35) reduced the proliferation of three human cancer cells, namely, oesophageal carcinoma (Aca-109), chronic myeloid leukemia (K562), and hepatoma (HepG2), with the IC50 of 23.7 µg·mL-1, 12.1 µg·mL−1 and >50.0 µg·mL−1, respectively [69]. 6β-acetoxy-2-ene-1-one-8β,14β-epoxy-13,15-abiatene-16,12-olide (56) demonstrated promising anticancer effect against the lung (NCI-H460) cell with 85% growth inhibition at 5 × 10−5 M. Compound (56) further activity against Leukemia (SR, CCRF-CEM and K-562), Breast (MD-MB-435) and Colon (HCT-15) and with over 95% growth inhibition [15].
Bauerenol (74) exhibited apoptosis-inducing potential against HepG2 cancer cells and growth-inhibitory effects. Bauerenol (74) inhibited the proliferation of retinoblastoma cells (SO-Rb50), with the IC50 of 10 μM (p < 0.05). Furthermore, bauerenol (74) suppressed the invasion and movement of SO-RB50 cells by (p < 0.05) [70].

5.5. Antinociceptive Activity

Simiarenol (81) isolated from S. zanzibariensis exhibited a noticeable antinociceptive effect with the 50% infectious dose (ID50) of 18.87 (14.6–24.4) mmol·kg−1. These results were more active compared to other reference drugs, such as dipyrone and aspirin, which are known as anti-inflammatory and analgesic drugs, with an ID50 of 133 and 162 mmol·kg-1, respectively [71,72].

5.6. Antidiabetic Activity

The water extract of S. glomerulata leaves revealed an inhibitory effect against α-glucosidase with the IC50 2.29 µg·mL−1 [53].

5.7. Antiviral Activity

Suregada multiflora revealed the presence of anti-human immunodeficiency virus-1 (HIV 1) protein, glycosylation-associated protein (GAP3), and displayed an inhibitory effect on the replication and infection of anti-HIV activity, and herpes simplex virus (HSV) [15,73]. S. zanzibariensis leaf extract revealed toxicity against herpes simplex virus 2 (HSV-2) with the IC50 of 11.5 µg·mL−1 and toxic on African green monkey kidney cells (GMK AH1) with the CC50 52 µg·mL−1. Zanzibariolides A (58) and B (59) and simiarenol (81) exhibited no anti-HSV-2 effect and displayed minor toxicity against GMK AH1 cells at ≥100 µM [45].

5.8. Cytotoxicity

The dichloromethane-methanol crude extract of S. multiflorum revealed promising cytotoxicity against 60-cell tumour panels conducted at the NCI [16]. According to Kigondua et al., the ethyl acetate extract of S. multiflorum stem was cytotoxic against the cancer cell (MDA-MB435) [74]. Ethanol extract of the S. multiflorum bark revealed cytotoxicity against cervical cancer (Hela cells). The leaves aqueous and methanol extracts of S. zanziberiensis revealed low toxicity towards human embryonic lung fibroblast (HELF) cells with a 50% cytotoxic concentration (CC50) of >20 µg·mL−1 [74].
Luo et al. reported that Jolkinolide B (35) revealed weak cytotoxicity against five human cancer cells, namely, Bel 7402, A549, (BGC 823), HCT-8, and A2780 with the IC50 of 5.95, 6.10, 5.84, 6,88, and 5.09 µg·mL−1, respectively [70]. 3-oxo-jolkinolide B (44) showed a moderate cytotoxic effect against HCT-8, A549, BGC 823, Bel 7402, and A2780 with the IC50 of 6,77, 8.03, 10, 7.20, and 6.81 µg·mL−1, respectively [64]. The treatment of HepG2 cells with bauerenol (74) reduced the growth significantly with a 50% growth inhibitory concentration of 25 µg·mL−1 [75].

5.9. Anti-Inflammatory

The stem bark of S. multiflora showed anti-inflammatory activity against lipopolysaccharide (LPS)-induced nitric oxide (NO) and prostaglandin E(2) (PGE(2)) releases in RAW264.7 cells [17]. Helioscopinolide A (1) was the most active compound against NO release with an IC50 of 9.1 μM than helioscopinolide C (2) with an IC50 of 24.5 μM [17].

5.10. Antioxidant

The antioxidant activities of helioscopinolide A (1) inhibited COX 2 and iNOS mRNA [17].

5.11. Anti-Allergic Activity

Helioscopinolide A (1), helioscopinolide C (2), and helioscopinolide I (3) exhibited significant anti-allergic effects towards antigen-induced β-hexosaminidase release with the IC50 of 26.5, 37.0 and 29.3 µM, respectively [33]. Ent-16-kauren-3β,15β,18-triol (60), ent-3-oxo-16-kauren-15β,18-diol (61), ent-16-kaurene-3β,15β-diol (62) and abbeokutone (63) revealed noticeable anti-allergic effect against antigen-induced β hexosaminidase release with the IC50 of 22.5, 22.9 28,7 and 42.1 µM, respectively [36].

5.12. Antileishmanial Activity

The aqueous extract of S. zanzibariensis leaves revealed anti-leishmanial activity when tested on Leishmania major promastigotes with a mortality percentage of 40.5 ± 1.99%. The methanol extract revealed good anti-leishmanial activity on Leishmania major amastigotes with a mortality percentage of 28.0 ± 2.11%. Nitrogen production macrophages infected with amastigotes of Leishmania major treated with the S. zanzibariensis aqueous and methanol extracts showed significant Nitric oxide concentrations at 4.0 ± 0.56 and 6.6 ± 0.63 µg·mL−1 at 1000 µg·mL−1 [74]. The ethanol extract of S. procera revealed good antileishmanial activity with the IC50 of ≤10 µg·mL−1 [76]. Gelomulide A (6) and G (12) displayed significant antileishmanial activity with the IC50 below 20 µg·mL−1 [47].

5.13. Antiplasmodial Activity

Methanol extract of S. zanzibariensis exhibited a good antiplasmodial effect against Plasmodium falciparum strains with the IC50 of 4.66 ± 0.22 µg·mL−1 chloroquine-resistant (W2) and 1.82 ± 0.07 µg·mL−1 chloroquine-sensitive (D6) [77]. Omulokoli et al. stated that S. zanzibariensis leaf extract revealed significant antiplasmodial activity with the IC50 of 1.5 µg·mL−1 against Plasmodium falciparum chloroquine-resistant (ENT36) and chloroquine-sensitive (K67) [77].
Table 2. Pharmacological activities of the Suregada genus.
Table 2. Pharmacological activities of the Suregada genus.
Plant SpeciesPlant PartExtractActivityEffectReferences
S. aequoreaUnspecifiedDichloromethaneAnticancerExhibited activity against different human cancer cells with the IC50 of <20 µg·mL−1.[35]
S. angustifoliaStem barkMethanolAntibacterialRevealed zone inhibition of S. aureus (32 mm), Enterobacter aerogenes (26 mm), E. coli (26 mm), and P. vulgaris (25 mm) at 20 mg·mL−1.[9]
ChloroformShowed zone inhibition of A. hydrophila (40 mm), K. pneumonia (37 mm), S. Aureus (32 mm), and E. coli (40 mm) at 20 mg·mL−1.
HexaneExhibited zone inhibition of A. hydrophila (29 mm), K. pneumonia (29 mm), P. vulgaris (25 mm), V. vulnificus (25 mm), V. parahaemolyticus (25 mm), V. cholera (25 mm) at 20 mg·mL−1.
S. glomerulataLeavesWaterAntidiabeticPotent inhibition against α-glucosidase with the IC50 of 2.29 µg·mL−1.[49]
S. multifloraRootsMethanol: Ethyl acetate (1:9)Insecticidal activityRevealed 100% mortality rate of Tribolium castaneum[61]
LeavesShowed a 40% mortality rate of Tribolium castaneum
Antibacterial and AntimicrobialRevealed mild activity against E. coli, Sh. Flexneri, B. subtilis, S. aureus, and P. aeruginosa with the of zone inhibition range of 5 ± 0.10 to 6 ± 0.13 mm.[7]
RootsExhibited significant activity against E. coli with zone inhibition of 13 ± 0.01 mm and MIC of 0.625 mg·mL−1.[61]
Stem barkUnspecifiedInflammatory activityExhibited NO inhibitory effect with the IC50 of 8.6 µg·mL−1.[17]
S. proceraUnspecifiedEthanolAnti-leishmanial activityExhibited strong activity, IC50 value ≤ 10 µg·mL−1[76]
S. zanzibariensisLeavesMethanolAnti-plasmodial activityRevealed good anti-plasmodial properties against Plasmodium falciparum strains (W2 and D6) with IC50 of 4.66 ± 0.22 µg·mL−1 and 1.82 ± 0.07 µg·mL−1.[74]
Showed anti-plasmodial activity (1.5 µg·mL−1) against Plasmodium falciparum ENT36 and K67 with the IC50 of 1.5 µg·mL−1.[71]
Aqueous extractAnti-leishmanial activityRevealed anti-leishmanial activity on Leishmanial major promastigotes and amastigotes with a mortality percentage of 40.5 ± 1.99%.[74]
Methanol extractsPossessed good anti-leishmanial activity on Leishmania major amastigotes with a mortality percentage of 28.0 ± 2.11%.
Revealed substantial differences in the production of NO by macrophages infected with Leishmania major amastigotes (6.6 ± 0.63 μM).
Aqueous extractsShowed a significant difference in the production of nitric oxide by macrophages infected with Leishmania major amastigotes (4.0 ± 0.56 μM).
In vitro cytotoxicityLow toxicity was observed against HELF cells with a cytotoxic concentration of 50% (CC50) value > 20 µg·mL−1.
Methanol extractsShowed low toxicity against HELF cells with the CC50 > 20 µg·mL−1.[78]
Stem barkDichloromethane/methanolAnticancerShowed potent anticancer activity against TK10 with the TGI and GI50 of 0.60 µg·mL−1 and 0.26 µg·mL−1.[50]
Revealed anticancer activity against UACC62 with the TGI and GI50 0.54 µg·mL−1 for and 0.25 µg·mL−1.[50]
Showed anticancer activity against MCF7 with the TGI and GI50 5.27 µg·mL−1 and 0.81 µg·mL−1.

6. Comparison of Ethnomedicinal Uses with the Pharmacological Uses

Several plant species of the Suregada genus are utilized by locals in traditional medicine against various ailments such as headaches and colds, dysentery, malaria, placenta apposition, epilepsy, skin diseases, worms, weakness, blood vomiting, piles, toothache, eczema, venereal diseases, pyrexia, lymphatic disorders, hepatitis, fungal infection, leprosy, fever, poisonous effects, stomach disorder, squint eye, gum disease, asthma, dysentery, vaginal candidiasis, abdominal pains, wound healing and ankylostomiasis and also as purgative, an astringent and against snakebite. Pharmacological studies were conducted on various species of this genus, such as anti-inflammatory, anticancer, antiviral, antidiabetic, antimicrobial, antileishmanial, antiplasmodial, cytotoxic, antioxidant, and insecticidal activity. A comparison of traditional medicinal uses of genus Suregada with the pharmacological studies is described as follows:
  • The methanol and hexane extracts of S. anguistifolia, showed a maximum antibacterial effect against E. coli, A. hydrophila, and K. pneumonia. A similar activity was observed in S. aureus in chloroform and methanol extracts of S. anguistifolia stem bark. Staphylococcus aureus bacteria cause toothache and skin infections [9]. The pharmacological results from this plant species support the claims of traditional medicinal uses of S. anguistifolia, where Indian people in Kanis utilize it to treat skin infections and toothache [9].
  • The wood of S. multiflora was reported to treat pyrexia, eczema, and venereal diseases, and the roots are utilized to treat lymphatic disorders and skin infections [17]. In Thailand, S. multiflora is utilized to treat skin diseases and inflammation [17]. Various solvent extracts from S. multliflora were screened for antibacterial and antimicrobial activity and exhibited effects against B. subtilis, P. aeruginosa, Shi. flexineri, S. aureus, and E. coli [62]. S. aureus is responsible for skin infections, gum diseases, eczema, and pyrexia (fever). The bacteria P. aeruginosa is responsible for lymphatic disorders, which can include swelling. E. coli and shi. flexineri responsible for pyrexia (fever) [76]. Helioscopinolide A (1) and epifriedelinol (75) isolated from S. multiflora revealed antibacterial activity that further substantiates the traditional uses claims of S. multiflora. Epifriedelinol (75) exhibited the highest zone inhibition against S. aureus. S. aureus is the bacteria responsible for skin infection, eczema, and gum diseases [57,59,71]. Suregadolide (4) isolated from S. multiflora showed antifungal activity, which confirms the claims of the traditional uses of the plant being utilized for treating fungal infections and skin disease [34].
  • In some regions, the granule products of this species can be prepared, which acts as a powerful organic herbicide [19]. When tested for insecticidal activity, the (1:9) methanol: ethyl acetate root extract of S. multiflora revealed a mortality rate of 100% for Tribolium castaneum at 50 mg·mL−1 dose in 12 h [61]. Furthermore, the dichloromethane extract of S. multiflora stem showed partial antibacterial activity with zone inhibition of 3 mm against X. campestris [55]. S. multiflora revealed an antibacterial activity against X. campestris, which is responsible for plant diseases and insecticidal activity, which confirms the claims that the granules of S. multiflora act as organic herbicide [55,78].
  • In Thailand, S. multiflora is used to treat inflammation [18]. The stem bark of S. multiflora showed anti-inflammatory properties against lipopolysaccharide (LPS)-induced nitric oxide (NO) and prostaglandin E (2) (PGE(2)) releases in RAW264.7 cells, and the anti-inflammatory mechanism on mRNA expression was carried out [17].
  • A mixture of S. multiflorum is mixed with other herbs it is used as an anticancer recipe [17]. Helioscopinolide A (5) and gelomulide E (12) isolated from S. multiflora showed anticancer activity against various types of cancer, namely, leukemia (CCRF CEM), leukemia (SR), leukemia (K-562), breast (MD-MB-435), and colon (HTC-15) which supports the claims of S. multiflora being used traditionally in the anticancer recipe.
  • S. zanzibariensis leaves are utilized to treat malaria. The leaf extract of S. zanzibariensis revealed high anti-plasmodial activity with the IC50 value of1.5 µg·mL−1) against Plasmodium falciparum K67 and ENT36 [77].
  • Giriama and Duruma people use a root decoction to treat body swelling [28]. Tanzanian people used the stem bark and root extract of S. zanzibariensis to treat ankylostomiasis caused by parasitic hookworms [25]. Nitrogen production macrophages infected with amastigotes of Leishmania major treated with the methanol and aqueous extracts of S. zanzibariensis showed significant Nitric oxide concentration at 4.0 ± 0.56 and 6.6 ± 0.63 µg·mL−1 at 1000 µg·mL−1 [74]. The potent activity of this species against Leishmania, a parasitic disease, supports the claim that S. zanzibariensis is used to treat ankylostomiasis and body swelling. Simiarenol (81) isolated from S. zanzibariensis exhibited noticeable antinociceptive properties with the ID50 of 18.87 (14.6–24.4) mmol·kg−1 [71,72]. The activity of Simiarenol validates the claims of S. zanziberiensis being traditionally used for chest and abdominal pains.

7. Conclusions

The objective of this review was to outline the previous findings on the genus Suregada focusing on phytochemicals, pharmacological activities, and medicinal uses of the extracts and phytochemicals isolated from Suregada the species. The results showed that the genus Suregada is important due to its traditional medicinal benefits. This genus contains compounds that could be further explored for treating various ailments.
The Suregada species are traditionally utilized in treating gum and hepatic diseases, mixed with other herbs, and used as an anticancer recipe to treat pyrexia, eczema, venereal diseases, lymphatic disorder, skin infection, skin infections, toothache, ankylostomiasis, gonorrhea, and stomach-ache. Pharmacological studies revealed that the compounds in the Suregada species exhibit diverse biological activity, including antibacterial, antimicrobial, antiplasmodial, anticancer, and antiviral as in Figure 13.
A significant number of investigations have been conducted on S. multiflora and S. zanzibariensis; nevertheless, other species have not been widely investigated. Suregada species, mainly. S. multiflora and S. zanzibariensis are utilized traditionally in the treatment of various illnesses. S. zanzibariensis root extract is drunk to treat gonorrhea, stomachache, pneumonia, hernia, chest pains, chicken pox, and as a purgative. There is a need for further evaluation of this species since the relationship between traditional and pharmacological uses is not clearly shown. The antimicrobial studies for S. zanzibariensis should be performed to substantiate the mentioned claims. Furthermore, S. zanzibariensis is traditionally used to treat vaginal candidiasis, which may be yeast or fungal infection; conducting antifungal candida studies to substantiate the claims is needed. Suregada multiflorum is traditionally used to treat venereal diseases and hepatitis. The antiviral activity of these plants and their phytochemicals should be studied. Future pharmacological and phytochemical investigations of African Suregada species should focus on other traditionally used and accepted species, such as S. procera, which is used to treat hemorrhoids and gonorrhea. The other six African species are accepted species, but their traditional uses are not known, namely, S. africana, S. croizatiana, S. gossweileri, S. ivorense, S. lithoxylia, and S. occidentale. Other Suregada species (S. decidua, S. boiviniana, and S. adenophora) have known traditional uses but have not been investigated for their pharmacological uses and phytochemistry.
The presence of biologically active tested phytochemicals in Suregada species could afford an important basis in the discovery of drugs. Moreover, most of the activities investigated so far are in vitro testing, and no in vivo screenings were performed. The biochemical interaction through which the extracts and isolated compounds of Suregada produce its pharmacological effects of displaying promising activities should be further investigated.

Author Contributions

Conceptualization, M.M.; methodology, M.M.; software, D.K.; validation, M.M., V.J.T. and M.C.; formal analysis, M.M.; investigation, M.M. and D.K.; resources, V.J.T.; data curation, M.C.; writing—original draft preparation, M.M.; writing—review and editing, M.M., O.G., M.K.L., R.N., G.F. and C.T.; visualization, M.M.; supervision, V.J.T.; project administration, D.K.; funding acquisition, V.J.T. All authors have read and agreed to the published version of the manuscript.

Funding

The authors would like to thank the South African National Research Foundation (NRF) for the funding. The research for which this review article is supported by the NRF Thuthuka Grants UID: 117898 (Dr. V.J. Tembu) and UID: 117872 (Prof. C. Tarirai).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data sharing is not applicable.

Conflicts of Interest

The authors declare that they have no known competing financial interest or personal relationship that could influence the work reported in this paper.

Lists of Abbreviations

A2780Human ovarian cancer cell line
Aca-109Human oesophageal carcinoma cell line
ATPAdenosine triphosphate
Baxpro-apoptosis gene
B16F10Mouse melanoma cell line
Bcl-2Anti-apoptosis gene
Bel 7402Human liver cancer cell
BGC 823Human stomach cancer cell
BT474Breast cancer cell line
CC5050% cytotoxic concentration
CCRF-CEMHuman leukemic lymphoblast cell line
COX-2Cyclooxygenase-2
CRCColorectal cancer cell line
D6chloroquine-sensitive
DCMDichloromethane
DNADeoxyribonucleic acid
DRCDemocratic Republic of Congo
ENT36chloroquine-resistant
ERKExtracellular signal-regulated kinase
GAP3Glycosylation-associated protein
GI50(50% growth inhibition)
Glut1, Glut3 and Glut4Glucose transporter genes
K-562Human chronic myeloid leukemia cell line
K67chloroquine-resistant
H37RaMycobacterium tuberculosis
HCT-8Human colon cancer cell line
HTC-15Human colon cancer cell line
HeLaHuman cervical cancer cell line
HELFHuman embryonic lung fibroblast
HepG2(hepatocellular carcinoma) Liver cancer cell line
Hk2Hexokinase 2
HIVHuman Immunodeficiency Virus
HSVHerpes simplex virus
HT29Human colon cancer cell line
IC12Minimum concentration that gives an inhibition zone of 12 mm diameter
IC50Half-maximal inhibitory concentration
iNOSInducible nitric oxide synthase
LdhaLactate dehydrogenase-A
LPSLipopolysaccharide
MCF7human breast cancer cell line
MDA-MB-231Epithelial, human breast cancer cell line
MDA-MB435Epithelial, human breast cancer cell line
MICMinimal inhibitory concentration
mRNAMessenger Ribonucleic acid
NCINational Cancer Institute
NCI-H460Non-small cell lung cancer
NCI-H490Lung cancer cell line
NONitric oxide
NRFNational Research Foundation
PGE(2)Prostaglandin E(2)
RAW 264.7Mouse macrophage cell line
ROSReactive oxygen species
SKBR3Breast cancer cell line
SRSpontaneous remission leukemia cell line
SW620Human colon cancer cell line
TGITotal growth inhibition
TK10Renal cancer
UACC62Melanoma cell line
U937Human leukemic cell line
W2chloroquine-resistant
WHOWorld Health Organisation
µg/mLMicrograms per milliliter
µmol/LMicromole per litre
µg/spotMicrograms per spot

References

  1. Plants of the World Online (Continuously Updated). Facilitated by the Royal Botanic Gardens, Kew. Available online: https://powo.science.kew.org/ (accessed on 11 August 2022).
  2. Radcliffe-Smith, A. Genera Euphorbiacearum; Royal Botanic Gardens, Kew: Richmond, UK, 2001. [Google Scholar]
  3. Radcliffe-Smith, A.; Hoffmann, P.; Ranaivojaona, R.; Ralimanan, A.H. Suregada celastroides Radcl.-Sm. & Petra Hoffm. (Euphorbiaceae), a new species from eastern Madagascar. Kew Bull. 2003, 58, 965–970. [Google Scholar]
  4. Wurdack, K.J.; Hoffmann, P.; Chase, M.W. Molecular phylogenetic analysis of uniovulate Euphorbiaceae (Euphorbiaceae sensu stricto) using plastid rbcL and trnL-F DNA sequences. Am. J. Bot. 2005, 92, 1397–1420. [Google Scholar] [CrossRef] [PubMed]
  5. Léonard, J. Notulae Systematicae XXIV. Note sur les genres Suregada Roxb. Ex Rottl. et Gelonium Roxb. Ex Willd. (Euphorbiaceae). Bull. Jard. Bot. L’état Brux. 1958, 28, 443–450. [Google Scholar] [CrossRef]
  6. Darbyshire, I.; Kordofani, M.; Farag, I. The Plants of Sudan and South Sudan: An Annotated Checklist; Royal Botanic Gardens, Kew: Richmond, UK, 2015. [Google Scholar]
  7. African Plant Database (Version 3.4.0). Conservatoire et Jardin Botaniques de la Ville de Genève and South African National Biodiversity Institute, Pretoria. Available online: http://africanplantdatabase.ch (accessed on 20 August 2022).
  8. Govaerts, R.; Frodin, D.G.; Radcliffe-Smith, A. World Checklist and Bibliography of Euphorbiaceae (and Pandaceae) 1-4: 1-1622; The Board of Trustees of the Royal Botanic Gardens, Kew: Richmond, UK, 2000. [Google Scholar]
  9. Venkatesan, M.; Viswanathan, M.B.; Ramesh, N.; Lakshmanaperumalsamy, P. Antibacterial potential from Indian Suregada angustifolia. J. Ethnopharmacol. 2005, 93, 349–352. [Google Scholar] [CrossRef] [PubMed]
  10. Norscia, I.; Borgognini-Tarl, S.M. Ethnobotanical reputation of plant species from two forests of Madagascar: A preliminary investigation. S. Afr. J. Bot. 2006, 72, 656–660. [Google Scholar] [CrossRef]
  11. Razafindraibe, M.; Kuhlman, A.R.; Rabarison, H.; Rakotoarimanana, V.; Rajeriarison, C.; Rakotoarivelo, N.; Randrianarivony, T.; Rakotoarivony, F.; Ludovic, R.; Randrianasolo, A.; et al. Medicinal plants used by women from Agnalazaha littoral forest (Southeastern Madagascar). J. Ethnobiol. Ethnomedicine 2013, 9, 1–13. [Google Scholar] [CrossRef]
  12. Reddy, A.M.; Babu, M.V.S.; Rao, R.R. Ethnobotanical study of traditional herbal plants used by local people of Seshachalam Biosphere Reserve in Eastern Ghats, India. Herba Pol. 2019, 65, 40–54. [Google Scholar] [CrossRef]
  13. Pulladiah, T.; Krishnamurthy, K.V.; Bahadur, B. Ethnobotany of India, Volume 2: Western Ghats and West Coast of Peninsular India; Apple Academic Press, Inc.: Palm Bay, FL, USA, 2017; p. 184. [Google Scholar]
  14. Lovett, J.C.; Ruffo, C.K.; Gereau, R.E. Field Guide to the Moist Forest Trees of Tanzania; The Society for Environmental Exploration: London, UK, 2005; p. 97. [Google Scholar]
  15. Choudhary, M.I.; Gondal, H.Y.; Abbaskha, A.; Jahan, I.A.; Parvea, M.; Nahar, N.; Rahman, A.U. Revisiting diterpene lactones of Suregada multiflora. Tetrahedron 2004, 60, 7933–7941. [Google Scholar] [CrossRef]
  16. Jahan, I.A.; Nahar, N.; Mosihuzzaman, M.; Shaheen, F.; Rahman, A.U.; Choudhary, M.I. Six new diterpenoids from Suregada multiflora. J. Nat. Prod. 2004, 67, 1789–1795. [Google Scholar] [CrossRef]
  17. Tewtrakul, S.; Subhadhirasakul, S.; Cheenpracha, S.; Yodsaoue, O.; Ponglimanont, C.; Karalai, C. Anti-inflammatory principles of Suregada multiflora against nitric oxide and prostaglandin E2 releases. J. Ethnopharmacol. 2011, 133, 63–66. [Google Scholar] [CrossRef]
  18. Patil, A.S. Ethnomedicinal uses of some plants used by Gond tribe of Gadchiroli district, Maharashtra. Indian J. Nat. Prod. Resour. 2016, 7, 56–62. [Google Scholar]
  19. Kumar, S.; Pandey, A.K.; Thakur, J.R. Plant extracts used as organic pesticides. J. Med. Plants Stud. 2017, 5, 117–120. [Google Scholar]
  20. Pal, D.C.; Sharma, S.K.; Das, M.; Sahu, R.K. Evaluation of hepatoprotective and in vitro antioxidant activity of Suregada multiflora (Bark) in Swiss Albino mice. Int. J. Pharm. Sci. 2011, 3, 127–130. [Google Scholar]
  21. Hartley, T.G. The ethnobotany of the Northern Cheyenne Indians of Montana. J. Ethnopharmacol. 2001, 74, 141–156. [Google Scholar]
  22. Jamaluddin, M.D.; Sayeed, A.; Khaleque, M.A.; Uddin, M.J. Traditional use of medicinal plants in Bangladesh to treat urinary tract infections and sexually transmitted diseases. Ethnobot. Res. Appl. 2015, 14, 119–133. [Google Scholar]
  23. Russof, L.L.; Dissanayake, M.D.M.S.; Amarasinghe, M.D.; Fonseka, D.M. Evaluation of selected forest tree species in the dry zone of Sri Lanka for wood strength properties. J. Trop. For. Sci. 2003, 15, 483–490. [Google Scholar]
  24. Fassil, A.; Gashaw, G. An ethnobotanical study of medicinal plants in chiro district, West Hararghe, Ethiopia. Afr. J. Plant Sci. 2019, 13, 309–323. [Google Scholar]
  25. Schmelzer, G.H.; Wageningen, A.G.F. Plant Resources of Tropical Africa; PROTA Foundation-Backhuys—CTA PROTA: Wageningen, The Netherlands, 2008; Volume 11, p. 582. [Google Scholar]
  26. Runyoro, D.K.B.; Ngassapa, O.D.; Matee, M.I.N.; Joseph, C.C.; Moshi, M.J. Medicinal plants used by Tanzanian traditional healers in the management of Candida infections. J. Ethnopharmacol. 2006, 106, 158–165. [Google Scholar] [CrossRef]
  27. Hedberg, I.; Hedberg, O.; Madati, P.J.; Mshigeni, K.E.; Mshiu, E.N.; Samuelsson, G. Inventory of plants used in traditional medicine in Tanzania. Part II. Plants of the families DilleniaceaeOpiliaceae. J. Ethnopharmacol. 1983, 9, 105–127. [Google Scholar] [CrossRef]
  28. Watt, J.M.; Breyer-Brandwijk, M.G. The Medicinal and Poisonous Plants of Southern and Eastern Africa, 2nd ed.; E. & S. Livingstone: London, UK, 1962. [Google Scholar]
  29. Innocent, E.; Joseph, C.C.; Gikonyo, N.K.; Nkunya, M.H.; Hassanali, A. Constituents of the essential oil of Suregada zanzibariensis leaves are repellent to the mosquito, Anopheles gambiae s.s. J. Insect Sci. 2010, 2010, 10–57. [Google Scholar]
  30. Monaco Encyclopaedia Suregada multiflora; Monaco Nature Encyclopedia: Monte Carlo, Monaco, 2018.
  31. Useful Tropical Plants. Available online: www.theferns.info (accessed on 15 August 2023).
  32. Suregada lanceolata-South Indian Suregada. Available online: www.flowersofindia.net (accessed on 18 August 2023).
  33. Available online: https://casabio.org/taxa (accessed on 5 August 2023).
  34. Jahan, I.A.; Nahar, N.; Mosihuzzaman, M.; Shaheen, F.; Parween, Z.; Rahman, A.U.; Choudhary, M.I. Novel diterpene lactones from Suregada multiflora. J. Nat. Prod. 2002, 65, 932–934. [Google Scholar] [CrossRef] [PubMed]
  35. Lee, C.L.; Chang, F.R.; Hsieh, P.W.; Chiang, M.Y.; Wu, C.C.; Huang, Z.Y.; Lan, Y.H.; Chen, M.; Lee, K.H. Cytotoxic ent-abietane diterpenes from Gelonium aequoreum. Phytochemistry 2008, 69, 276–287. [Google Scholar] [CrossRef] [PubMed]
  36. Cheenpracha, S.; Yodsoue, O.; Karalai, C.; Ponglimanont, C.; Subhadhirasakul, S.; Tewtrakul, S.; Kanjana-Opas, A. Potential anti-allergic ent-kaurene diterpenes from the bark of Suregada multiflora. Phytochemistry 2006, 67, 2630–2634. [Google Scholar] [CrossRef] [PubMed]
  37. Gondal, H.Y.; Choudhary, M.I. New Diterpene Lactone from the leaves of Suregada multiflora. Chem. Nat. Compd. 2016, 52, 421–423. [Google Scholar] [CrossRef]
  38. Hanson, J.R. Diterpenoids of terrestrial origin. Nat. Prod. Rep. 2015, 32, 1654–1663. [Google Scholar] [CrossRef] [PubMed]
  39. Vasas, A.; Hohmann, J. Euphorbia diterpenes: Isolation, structure, biological activity, and synthesis (2008–2012). Chem. Rev. 2014, 114, 8579–8612. [Google Scholar] [CrossRef]
  40. Wu, Q.C.; Tang, Y.P.; Ding, A.W.; You, F.Q.; Zhang, L.; Duan, J.A. 13C-NMR data of three important diterpenes isolated from Euphorbia species. Molecules 2009, 14, 4454–4475. [Google Scholar] [CrossRef]
  41. Dewick, M. Medicinal Natural Products: A Biosynthetic Approach, 3rd ed.; John Wiley & Sons, Ltd.: Chichester, UK, 2006; ISBN 978-0-47074-168-9. [Google Scholar]
  42. Zhang, J.; He, J.; Wang, X.X.; Shi, Y.X.; Zhang, N.; Ma, B.Z.; Zhang, W.K.; Xu, J.K. Ent-abietane diterpenoids and their probable biogenetic precursors from the roots of Euphorbia fischeriana. RSC Adv. 2017, 7, 55859–55865. [Google Scholar] [CrossRef]
  43. Sandjo, L.P.; Kuete, V. Diterpenoids from the Medicinal Plants of Africa. In Medicinal Plant Research in Africa; Elsevier: Amsterdam, The Netherlands, 2013; pp. 105–121. [Google Scholar]
  44. Rubinger, M.M.M.; Castelo-Branco, P.d.A.; Guilardi, S.; Souza, E.M.R.; Gambardella, M.T.d.o.P.; Borges, E.E.L.; Ferreira-Alves, D.L.; Pilo-Veloso, D. Preparation, X-ray structural studies, and plant growth regulatory activity of methyl 6α,7β-thiocarbonyldioxyvouacapan-17β-oate. J. Braz. Chem. Soc. 2004, 15, 219–223. [Google Scholar] [CrossRef]
  45. Sakan, F.; Iwashita, T.; Hamanaka, N. Structures of Metasequoic Acid A and B. Chem. Lett. 1988, 17, 123–126. [Google Scholar] [CrossRef]
  46. Kalenga, T.M.; Mollel, J.T.; Said, J.; Orthaber, A.; Ward, J.S.; Atilaw, Y.; Umereweneza, D.; Ndoile, M.M.; Munissi, J.J.E.; Rissanen, K.; et al. Modified ent-Abietane ditepenoids from the leaves of Suregada zanzibariesis. J. Nat. Prod. 2022, 85, 2135–2141. [Google Scholar] [CrossRef] [PubMed]
  47. Gondal, H.Y.; Nisar, M.; Choudhary, M.I. Antileishmanial activity of diterpene lactones from Suregada multiflora and their semisynthetic derivatives. Curr. Bioact. Compd. 2020, 16, 53–57. [Google Scholar] [CrossRef]
  48. Talapatra, S.K.; Das, G.; Talapatra, B. Stereostructures and molecular conformations of six diterpene lactones from Gelonium multiflorum. Phytochemistry 1989, 28, 1181–1185. [Google Scholar] [CrossRef]
  49. Talapatra, B.; Das, G.; Das, A.K.; Biswas, K.; Talapatra, S.K. Stereostructures and conformations of four diterpene lactones from Gelonium multiflorum. Phytochemistry 1998, 49, 1353–1359. [Google Scholar] [CrossRef]
  50. Mangisa, M.; Tembu, V.J.; Fouche, G.; Nthambeleni, R.; Peter, X.; Langat, M.K. Ent-abietane diterpenoids from Suregada zanziberiensis Baill. (Euphorbiaceae), their cytotoxic and anticancer properties. Nat. Prod. Res. 2018, 33, 3240–3247. [Google Scholar] [CrossRef]
  51. He, S.L.; Yan, R.Y.; Zuo, L.; Chen, R.Y. Ent-Abietane and ent-Kaurane diterpenoids from the Roots of Suregada glomerulata. Planta Med. 2009, 75, 641–646. [Google Scholar] [CrossRef]
  52. Yan, R.Y.; Tan, Y.X.; Cui, X.Q.; Chen, R.; Yu, D.Q. Diterpenoids from the roots of Suregada glomerulata. J. Nat. Prod. 2008, 71, 195–198. [Google Scholar] [CrossRef]
  53. Yan, R.Y.; Wang, H.Q.; Lui, C.; Chen, R.Y.; Yu, D.Q. Three new water-soluble alkaloids from the leaves of Suregada glomerulata (Blume) Baill. Fitoterapia 2011, 82, 247–250. [Google Scholar] [CrossRef]
  54. Sengupta, P.; Khastgir, H.N. Terpenoids, and related compounds-III: Bauerenol and multiflorenol from gelonium multiflorum A. Juss. The structure of multiflorenol. Tetrahedron 1963, 19, 123–132. [Google Scholar] [CrossRef]
  55. Kite, G.C.; Hoffmann, P.; Lees, D.C.; Wurdack, K.J.; Gillespie, L.J. α-Homonojirimycin and other polyhydroxyalkaloids in Suregada Roxb. ex Rottl. (Euphorbiaceae). Biochem. Syst. Ecol. 2005, 33, 1183–1186. [Google Scholar] [CrossRef]
  56. Gondal, H.Y. Isolation and Biotransformation of Some Bioactive Compounds from Medicinal Plants. Ph.D. Thesis, H.E.J. Research Institute of Chemistry, International Center for Chemical Sciences, University of Karachi, Karachi, Pakistan, 2004; pp. 1–8. [Google Scholar]
  57. Parveen, N.; Khan, N.U. Luteolin 7, 4′-dimethyl ether 3′-glucoside from Gelonium multiflorum. Phytochemistry 1987, 26, 2130–2131. [Google Scholar] [CrossRef]
  58. Das, B.; Chakravarthy, A.K. Three flavone glycosides from gelonium multiflorum. Phytochemistry 1993, 33, 493–496. [Google Scholar] [CrossRef]
  59. Yan, R.Y.; Wang, H.Q.; Kang, J.; Chen, R.Y. Pyrrolidine-type iminosugars from leaves of Suregada glomerulata. Carbohydr. Res. 2014, 384, 9–12. [Google Scholar] [CrossRef]
  60. Khuntong, S.; Sudprasert, W. Extraction and basic testing for antibacterial activity of the chemical constituents in Suregada multiflorum. Kasetsart J. Nat. Sci. 2008, 42, 429–434. [Google Scholar]
  61. Islam, M.S.; Zahan, R.; Alam, M.B.; Nazn, M.; Sarkar, G.C.; Mosaddik, M.A.; Haque, M.E. Studies on antibacterial and insecticidal activities of Suregada multiflora. LARCJI 2011, 2, 62–67. [Google Scholar]
  62. Valente, C.; Pedro, M.; Duarte, A.; Nascimento, M.S.J.; Abreu, P.M.; Ferreira, M.J. Bioactive diterpenoids, a new jatrophane and two ent-abietanes, and other constituents from Euphorbia pubescens. J. Nat. Prod. 2004, 67, 902–904. [Google Scholar] [CrossRef] [PubMed]
  63. Kannathasan, K.; Senthilkumar, A.; Venkatesalu, V. Crystal structure and antibacterial evaluation of epifriedelinol isolated from Vitex peduncularis Wall. ex Schauer. Arab. J. Chem. 2019, 12, 2289–2292. [Google Scholar] [CrossRef]
  64. Lu, Z.Q.; Guan, S.H.; Li, X.N.; Chen, G.T.; Zhang, J.Q.; Huang, H.L.; Liu, X.; Guo, D.A. Cytotoxic diterpenes from Euphorbia helioscopia. J. Nat. Prod. 2008, 71, 873–876. [Google Scholar] [CrossRef]
  65. Wang, Y.; Yu, X.; Wang, L.; Zhang, F.; Zhang, Y. Research Progress on Chemical Constituents and Anticancer Pharmacological Activities of Euphorbia lunulata Bunge. BioMed Res. Int. 2020, 2020, 3618941. [Google Scholar] [CrossRef]
  66. Wang, J.H.; Zhou, Y.J.; Bai, X.; He, P. Jolkinolide B from Euphorbia fischeriana Steud induces apoptosis in human leukemic U937 cells through PI3K/Akt and XIAP pathways. Mol. Cell. 2011, 32, 451–457. [Google Scholar] [CrossRef]
  67. Gao, C.; Yan, X.; Wang, B. Jolkinolide B induces apoptosis and inhibits tumor growth in mouse melanoma B16F10 cells by altering glycolysis. Sci. Rep. 2016, 6, 36114. [Google Scholar] [CrossRef] [PubMed]
  68. Sun, C.; Cui, H.; Yang, H.; Du, X.; Yue, L.; Liu, J.; Lin, Y. Anti-metastatic effect of jolkinolide B and the mechanism of activity in breast cancer MDA-MB-231 cells. Oncol. Lett. 2015, 10, 1117–1122. [Google Scholar] [CrossRef] [PubMed]
  69. Chen, Y.; Peng, J.; Cao, S. Bauerenol inhibits proliferation, migration, and invasion of retinoblastoma cells via induction of apoptosis, autophagy, and cell cycle arrest. Trop. J. Pharm. Res. 2022, 21, 1377–1382. [Google Scholar] [CrossRef]
  70. Luo, H.; Wang, A. Induction of apoptosis in K562 cells by jolkinolide B. Can. J. Physiol. Pharmacol. 2006, 84, 959–965. [Google Scholar] [CrossRef]
  71. Aljamali, N.M.; Al-zubaidy, Z.H.; Enad, A.H. Bacterial infection and common bacterial diseases: A Review. Pharm. Nanotechnol. 2021, 3, 13–23. [Google Scholar]
  72. Kuroshima, K.N.; Campos-Buzzi, F.; Yunes, R.A.; Monache, F.D.; Filho, V.C. Chemical composition and antinociceptive properties of Hyeronima alchorneoides. Leaves. Pharm. Biol. 2005, 43, 573–578. [Google Scholar] [CrossRef]
  73. Bourinbaiar, A.S.; Lee-Huang, S. The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against herpes simplex virus infection in vitro. Biochem. Biophys. Res. Commun. 1996, 219, 923–929. [Google Scholar] [CrossRef]
  74. Kigondua, E.V.M.; Rukunga, G.M.; Keriko, J.M.; Tonui, W.K.; Gathirwa, J.W.; Kirira, P.G.; Irungu, B.; Ingonga, J.M.; Ndiege, I.O. Anti-parasitic activity and cytotoxicity of selected medicinal plants from Kenya. J. Ethnopharmacol. 2009, 123, 504–50963. [Google Scholar] [CrossRef]
  75. Kumar, S.P.; Viswanathan, M.B.G.; Venkatesan, M.; Balakrishna, K. Bauerenol, a triterpenoid from Indian Suregada angustifolia: Induces reactive oxygen species-mediated P38MAPK activation and apoptosis in human hepatocellular carcinoma (HepG2) cells. Tumor Biol. 2017, 39, 1010428317698387. [Google Scholar]
  76. Muhammad, I.; Midiwo, J.; Tekwani, B.L.; Samoylenko, V.; Sahu, R.; Machumi, F.; Rahman, A.A.; Walker, L.A.; Hester, J.P. Antileishmanial Activity of Kenyan Medicinal Plants; University of Nairobi: Nairobi, Kenya, 2008; pp. 1–2. [Google Scholar]
  77. Omulokoli, E.; Khan, B.; Chhabra, S.C. Antiplasmodial activity of four Kenyan medicinal plants. J. Ethnopharmacol. 1997, 56, 133–137. [Google Scholar] [CrossRef]
  78. Mohana, D.C.; Raveesha, K.A. Antibacterial activity of Caesalpinia coriaria (Jacq.) Willd. against plant pathogenic Xanthomonas pathovars: An eco-friendly approach. JAST 2006, 2, 317–327. [Google Scholar]
Figure 2. Representation of different metabolites in genus Suregada.
Figure 2. Representation of different metabolites in genus Suregada.
Pharmaceuticals 16 01390 g002
Scheme 1. Suggested biosynthesis of some ent-abietane lactones including Jolkinolide B (35). Oxidation of ent-neoabietadiene led to the formation of intermediate (a). Oxidation of (a) could lead to the production of intermediate (b). Intermediate (c) was produced from a possible demethylation of (b). Intermediate see may undergo cyclization to yield (d). Dehydration of intermediate (d) produces intermediate (e).
Scheme 1. Suggested biosynthesis of some ent-abietane lactones including Jolkinolide B (35). Oxidation of ent-neoabietadiene led to the formation of intermediate (a). Oxidation of (a) could lead to the production of intermediate (b). Intermediate (c) was produced from a possible demethylation of (b). Intermediate see may undergo cyclization to yield (d). Dehydration of intermediate (d) produces intermediate (e).
Pharmaceuticals 16 01390 sch001
Figure 3. (a) Abiatane-type diterpenoids were isolated from Suregada species. (b) Abiatane-type diterpenoids were isolated from Suregada species. (c) Abiatane-type diterpenoids were isolated from Suregada species.
Figure 3. (a) Abiatane-type diterpenoids were isolated from Suregada species. (b) Abiatane-type diterpenoids were isolated from Suregada species. (c) Abiatane-type diterpenoids were isolated from Suregada species.
Pharmaceuticals 16 01390 g003aPharmaceuticals 16 01390 g003bPharmaceuticals 16 01390 g003c
Scheme 2. Suggested biosynthesis for compounds 58 and 59.
Scheme 2. Suggested biosynthesis for compounds 58 and 59.
Pharmaceuticals 16 01390 sch002
Figure 4. Structures of kaurene and ent-pimarane-type diterpenoids from Suregada species.
Figure 4. Structures of kaurene and ent-pimarane-type diterpenoids from Suregada species.
Pharmaceuticals 16 01390 g004
Figure 5. Structures of triterpenoids isolated from S. multiflora.
Figure 5. Structures of triterpenoids isolated from S. multiflora.
Pharmaceuticals 16 01390 g005
Figure 6. Structures of fatty alcohol, steroidal glycoside, and phytosterols isolated from S. angustifolia.
Figure 6. Structures of fatty alcohol, steroidal glycoside, and phytosterols isolated from S. angustifolia.
Pharmaceuticals 16 01390 g006
Figure 7. Structures of alkaloids isolated from S. glomerulata.
Figure 7. Structures of alkaloids isolated from S. glomerulata.
Pharmaceuticals 16 01390 g007
Figure 8. Structures of flavones isolated from S. multiflora.
Figure 8. Structures of flavones isolated from S. multiflora.
Pharmaceuticals 16 01390 g008
Figure 9. Structures of lignans isolated from S. multiflora.
Figure 9. Structures of lignans isolated from S. multiflora.
Pharmaceuticals 16 01390 g009
Figure 10. Structures of amino acids isolated from S. glomerulata.
Figure 10. Structures of amino acids isolated from S. glomerulata.
Pharmaceuticals 16 01390 g010
Figure 11. Structures of pyrimidines, purine nucleoside, and pyridines isolated from S. glomerulata.
Figure 11. Structures of pyrimidines, purine nucleoside, and pyridines isolated from S. glomerulata.
Pharmaceuticals 16 01390 g011
Figure 12. Structures of pyrrolidine-type iminosugars isolated from S. glomerulata.
Figure 12. Structures of pyrrolidine-type iminosugars isolated from S. glomerulata.
Pharmaceuticals 16 01390 g012
Figure 13. Summary of the ethnomedicinal, phytochemistry, and pharmacological properties of Suregada species.
Figure 13. Summary of the ethnomedicinal, phytochemistry, and pharmacological properties of Suregada species.
Pharmaceuticals 16 01390 g013
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Mangisa, M.; Kemboi, D.; Fouche, G.; Nthambeleni, R.; Langat, M.K.; Tarirai, C.; Cheek, M.; Gonyela, O.; Tembu, V.J. Ethnomedicinal Uses, Phytochemistry and Pharmacological Properties of Suregada Genus: A Review. Pharmaceuticals 2023, 16, 1390. https://doi.org/10.3390/ph16101390

AMA Style

Mangisa M, Kemboi D, Fouche G, Nthambeleni R, Langat MK, Tarirai C, Cheek M, Gonyela O, Tembu VJ. Ethnomedicinal Uses, Phytochemistry and Pharmacological Properties of Suregada Genus: A Review. Pharmaceuticals. 2023; 16(10):1390. https://doi.org/10.3390/ph16101390

Chicago/Turabian Style

Mangisa, Mandisa, Douglas Kemboi, Gerda Fouche, Rudzani Nthambeleni, Moses Kiprotich Langat, Clemence Tarirai, Martin Cheek, Odwa Gonyela, and Vuyelwa Jacqueline Tembu. 2023. "Ethnomedicinal Uses, Phytochemistry and Pharmacological Properties of Suregada Genus: A Review" Pharmaceuticals 16, no. 10: 1390. https://doi.org/10.3390/ph16101390

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop